Author + information
- Hailing Li,
- Xianlin Zhang,
- Kai Tang,
- Dongdong Zhao,
- Wenhui Peng and
- Yawei Xu
Microfibrillar-associated protein 4 (MFAP4) is an integrin ligand localized to extracellular matrix fibers in the vascular wall. However, its potential value as a prognostic biomarker in atrial fibrillation (AF) is unknown. We aimed to examine the association between plasma MFAP4 levels with AF occurrence and prognosis.
Plasma MFAP4 levels were measured in 92 patients with AF and 71 control subjects without AF. MFAP4 levels were determined by enzyme-linked immunoabsorbent assays (ELISA). Linear and logistic multivariate regression analyses were performed and receiver operating characteristic (ROC) analysis was used to determine the potential value of MFAP4 for predicting the incidence of AF and AF complications.
Higher plasma MFAP4 levels were observed in patients with AF compared with control individuals without AF (2.01 ± 0.07 vs. 1.71 ± 0.06 ng/ml, p=0.003). By ROC analysis, we found MFAP4 had potential value in the diagnosis and prediction of AF occurrence (the area under the curves was 0.618, p=0.01). Furthermore, a positive correlation was established between plasma MFAP4 levels with left atrial diameter (LAD), NT-proBNP levels, CHA2DS2-VASc scores and related risk factors of AF. With multivariate analyses, MFAP4 were also found to be an independent determinant of LAD and plasma NT-proBNP in AF patients.
Plasma MFAP4 levels were increased in AF patients. MFAP4 was an independent determinant of AF occurrence and AF prognosis such as atrial enlargement, stroke and heart failure. Our findings suggested that MFAP4 could serve as a novel biomarker of AF, as well as a biomarker to identify ‘high risk’ AF patients.